13 February 2018 - Patients with severe plaque psoriasis are a step closer to getting NHS funded access to Leo Pharma’s Kyntheum, after cost regulators published final draft guidelines backing the drug.

Leo Pharma’s Kyntheum (brodalumab) is a novel biologic approved in Europe in July last year, and is the first and only psoriasis treatment to target the L-17 receptor.

By binding to this specific receptor on the cells of the skin, Kyntheum blocks the biological activity of several pro-inflammatory IL-17 cytokines involved in plaque formation, offering a different mechanism of action to all other psoriasis biologics currently available, which target free inflammatory mediators.

Read Pharma Times article